Detalhe da pesquisa
1.
Part II: piperazinyl-glutamate-pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation.
Bioorg Med Chem Lett
; 20(4): 1388-94, 2010 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20097563
2.
Structure-based drug design enables conversion of a DFG-in binding CSF-1R kinase inhibitor to a DFG-out binding mode.
Bioorg Med Chem Lett
; 20(5): 1543-7, 2010 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20137931
3.
Piperazinyl-glutamate-pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation.
Bioorg Med Chem Lett
; 19(16): 4657-63, 2009 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19604694
4.
Piperazinyl-glutamate-pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation.
Bioorg Med Chem Lett
; 19(21): 6148-56, 2009 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19796941
5.
Discovery of potent, nonsystemic apical sodium-codependent bile acid transporter inhibitors (Part 1).
J Med Chem
; 48(18): 5837-52, 2005 Sep 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-16134950
6.
Discovery of potent, nonsystemic apical sodium-codependent bile acid transporter inhibitors (Part 2).
J Med Chem
; 48(18): 5853-68, 2005 Sep 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-16134951
7.
Chiral N,N-disubstituted trifluoro-3-amino-2-propanols are potent inhibitors of cholesteryl ester transfer protein.
J Med Chem
; 45(18): 3891-904, 2002 Aug 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-12190312
8.
Piperazinyl glutamate pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation.
J Med Chem
; 53(5): 2010-37, 2010 Mar 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-20141147